Journal: Nature Communications
Article Title: Low-intensity pulsed ultrasound-mediated nose-to-brain co-delivery of β-blockers and aPD-L1 enhances glioblastoma immunotherapy
doi: 10.1038/s41467-026-76103-4
Figure Lengend Snippet: a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g Immunohistochemical images of tumor sections were examined at 15 days (Ki67 and PCNA, n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
Article Snippet: Immunohistochemical staining utilized PCNA (AC058, PCNA Mouse mAb, Abclonal) and Ki67 (A26755PM, Ki67 Rabbit PolymAb®, Abclonal) antibodies, with technical assistance from Nanjing Youmeng Biotechnology Co., Ltd. Tumor sections underwent immunofluorescence staining using a TUNEL assay kit (Beyotime Biotech, Shanghai, China).
Techniques: Sequencing, Magnetic Resonance Imaging, Immunohistochemical staining